Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia

International Urology and Nephrology

Volumn 41, Issue 2, 2009, Pages 287-292

  Guven, Esref O ^a   Balbay, Mevlana D ^a   Mete, Kilciler ^b   Serefoglu, Ege C ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Benign prostate hyperplasia; Lower urinary tract symptoms; Phosphodiesterase inhibitors; Sildenafil; Uroflowmetry

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; ECHOGRAPHY; ERECTILE DYSFUNCTION; FLOW RATE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; PROSTATE HYPERTROPHY; RATING SCALE; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT RESPONSE; URINE VOLUME; UROFLOWMETRY;

ADMINISTRATION, ORAL; AGED; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSTATIC HYPERPLASIA; PURINES; SULFONES; TIME FACTORS; URINATION; URODYNAMICS;

EID: 67349088795     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9423-y     Document Type: Article

References (24)

1. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Emgelmann U (2003) Epidemiology of erectile dysfunction: Results of the "Cologne Male Survey". Int J Impot Res 15:63-71. doi: 10.1038/sj.ijir.3900949
2. Mulhall JP, Guhring P, Parker M, Hopps C (2006) Assessment of the effect of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3:662-667. doi: 10.1111/ j.1743-6109.2006.00259.x
3. Ponholzer A, Temml C, Obermayr R, Madersbacher S (2004) Association between lower urinary tract symptoms and erectile dysfunction. Urology 64(4):772-776. doi: 10.1016/j.urology.2004.05.025
4. Mc Vary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomised double blind trial. J Urol 177:1071-1077. doi: 10.1016/j.juro.2006.10.055
5. Mc Vary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al (2007) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177:1401-1407. doi: 10.1016/ j.juro.2006.11.037
6. Kaplan AS, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717-1723. doi: 10.1016/ j.eururo.2007.01.033
7. Andersson KE, Uckert S, Stief C, Hedlund P (2007) Phosphodiesterases and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26:928-933. doi: 10.1002/nau.20485
8. Kaplan AS, Gonzales RR (2007) Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9(2):73-77
9. Tinel H, Stelte-Ludwig B, Hütter J, Sandner P (2006) Per-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98:1259-1263. doi: 10.1111/j.1464-410X.2006.06501.x
10. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al (2007) Characterization and functional role of an androgen-dependent PDE5 activity in bladder. Endocrinology 148(3):1019-1029. doi: 10.1210/ en.2006-1079
11. Ückert S, Küthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166:2484-2490. doi: 10.1016/ S0022-5347(05)65621-2
12. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H (1995) Effects of nitric oxide on human and canine prostates. Urology 45(3):440-446. doi: 10.1016/S0090-4295(99)80013-2
13. Malavaud B, Rostaign L, Tran-Van T, Tack I, Ader JL (2001) Transient renal effects of sildenafil in male kidney transplantation recipients. Transplantation 72(7):1331-1333. doi: 10.1097/00007890-200110150-00027
14. Rostaign L, Tran-Van T, Ader JL (2000) Increased glomerular filtration rate in kidney transplant recipients who take sildenafil. N Engl J Med 342(22):1679-1680. doi: 10.1056/NEJM200006013422217
15. Sairam K, Kulinskaya E, Mcnicholas TA, Boustead GB, Hanbury DC (2002) Sildenafil influences lower urinary tract symptoms. BJU Int 90:836-839. doi: 10.1046/j.1464-410X.2002.03040.x
16. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH (2003) Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur Urol 44:588-594. doi: 10.1016/ S0302-2838(03)00358-0
17. Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, DiSanto ME (2002) Enhanced force generation by corpus cavernosum smooth muscle in rabbits with partial bladder outlet obstruction. J Urol 167:2636-2644. doi: 10.1016/S0022-5347(05)65050-1
18. Hiebele JP, Ruffolo RR Jr (1996) The use of alpha adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview. Pharmacol Res 33:145-160. doi: 10.1006/ phrs.1996.0022
19. Gingell C, Sultana SR, Wulf MB, Gepi-Attee S (2004) Duration of action of sildenafil citrate in men with erectile dysfunction. J Sex Med 1:179-184. doi: 10.1111/j.1743-6109.2004.04026.x
20. Cook AL, Haynes JM (2004) Protein kinase G-II mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16:253-261. doi: 10.1016/S0898-6568(03)00134-7
21. Adolfsson PL, Ahlstrand C, Varenhorst E, Svensson SP (2002) Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: Sildenafil and papaverine generate inhibition. Prostate 51:50-58. doi: 10.1002/pros.10077
22. Qiu Y, Kraft P, Carig EC, Liu X, Haynes-Johnson D (2002) Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 59:145-149. doi: 10.1016/S0090-4295(01)01471-6
23. Haaga JR, Exner A, Fei B, Seftel A (2007) Semiquantitative imaging measurement of baseline and vasomodulated normal prostatic blood flow using sildenafil. Int J Impot Res 19(1):110-113. doi: 10.1038/ sj.ijir.3901486
24. Rashid A (2005) The efficacy and safety of PDE5 inhibitors. Clin Cornerstone Int 7(1):47-56. doi: 10.1016/S1098-3597(05)80048-1